Rivaroxaban, a popular oral blood clot medication, is associated with the highest risk of bleeding of any medication used to treat atrial fibrillation, or blood clots in the veins. This was demonstrated by a study presented at the annual meeting of the American Society of Hematology (ASH).
If a blood clot or atrial fibrillation is detected, patients may be prescribed anticoagulants, blood thinners, to prevent clot formation in the future. Atrial fibrillation is a type of heart rhythm disorder that significantly increases the risk of blood clots and stroke. The three most commonly prescribed medications are rivaroxaban (Xarelto), apixaban (Eliquis), and warfarin.
The scientists analyzed data from 100 patients collected within a year of being prescribed anticoagulants. Rivaroxaban resulted in nearly forty bleeding events, and warfarin and apixaban resulted in 25 events. Warfarin has been associated with more serious bleeding.
The incidence of blood clots was higher with apixaban compared with warfarin. The lowest risk of death was observed with apixaban, but the findings need to be reexamined in larger studies.
Previous scientists I learnedIt turns out that refusing heart disease treatment increases the risk of death by 400 percent.